This is a preview of subscription content, log in via an institution to check access.
Notes
2014 US dollars
Reference
Hirt C, et al. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. Applied Health Economics and Health Policy : 6 Jun 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00489-0
Rights and permissions
About this article
Cite this article
Ponatinib cost effective third-line option for chronic phase CML. PharmacoEcon Outcomes News 831, 25 (2019). https://doi.org/10.1007/s40274-019-6013-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6013-4